BlossomHill Therapeutics (BLSM) vs MiMedx Group (MDXG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 11, 2026.
Summary
MiMedx Group is the larger company by market cap ($681.5 million vs $555.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLSM | MDXG |
|---|---|---|
| Share price | $17.48 | $4.67 |
| Market cap | $555.60M | $681.51M |
| 1-day change | +3.55% | +1.08% |
| YTD return | — | -31.02% |
| 1-year return | — | -28.70% |
| 5-year return | — | -30.92% |
| P/E ratio (TTM) | — | 116.75 |
| Forward P/E | — | 23.35 |
| EPS (TTM) | $-4.70 | $0.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.99 | $7.97 |
| 52-week low | $15.25 | $3.03 |
| Distance from 52-week high | -37.55% | -41.41% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +102.52% | +58.46% |
| Average volume | 258.35K | 1.22M |
| Shares outstanding | 31.78M | 145.93M |
| Employees | 69 | 808 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About BlossomHill Therapeutics
BLSM stock →BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS).
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About MiMedx Group
MDXG stock →MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare.
Health Care · Medical/Dental Instruments · 808 employees
BLSM vs MDXG FAQ
Which is bigger, BlossomHill Therapeutics or MiMedx Group?
MiMedx Group (MDXG) is larger, with a market capitalization of $681.51M compared with $555.60M for BlossomHill Therapeutics (BLSM).
Are BlossomHill Therapeutics and MiMedx Group in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for BlossomHill Therapeutics and Medical/Dental Instruments for MiMedx Group.